Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453180 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
A Phase 2 study of Autistic Disorder and Asperger Syndrome, sponsored by Indiana University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00453180 is a Phase 2 study of Autistic Disorder and Asperger Syndrome that has completed, run by Indiana University School of Medicine. The registered enrollment target is 31 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00453180, a Phase 2 study of Autistic Disorder and Asperger Syndrome, has completed, sponsored by Indiana University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether treatment with oral N-acetylcysteine (NAC) will improve behavior problems often associated with autism spectrum disorders.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
Study Locations (1)
Indiana
- Riley Hospital, Riley Child and Adolescent Psychiatry Clinic - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453180
The ClinicalTrials.gov registry entry for NCT00453180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (72% lower). The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00453180 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00453180 about?
NCT00453180 is a clinical study titled "A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders". The purpose of this study is to determine whether treatment with oral N-acetylcysteine (NAC) will improve behavior problems often associated with autism spectrum disorders.
What is the current status of trial NCT00453180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2007-03. Estimated completion is 2009-11.
What conditions does trial NCT00453180 study?
This clinical trial studies the following conditions: Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive.
What interventions are being tested in trial NCT00453180?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00453180?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00453180 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
COMPLETED · Phase 2
-
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
Donepezil HCl & Cognitive Deficits in Autism
COMPLETED · Phase 2
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.